Skip to main content

Frontier Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference

BOSTON and SOUTH SAN FRANCISCO, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation, a clinical-stage precision medicines company unlocking the proteome to develop small molecule oncology and immunology drugs against previously undruggable disease-causing targets, today announced that Chris Varma, Ph.D., co-founder, chair, and chief executive officer of Frontier Medicines, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 3:30 p.m. PST.

About Frontier Medicines
Frontier Medicines is a clinical-stage precision medicine company pioneering groundbreaking medicines to transform treatment for genetically defined patient populations, starting with oncology and immunology. Our proprietary chemoproteomics-powered drug discovery engine, the Frontier™ Platform, leverages covalent chemistry and machine learning to unlock difficult-to-drug, disease-causing proteins for drug development. Today, we are advancing a diversified pipeline of wholly owned precision medicines against the most critical drivers of cancer and high-value immunology programs. For more information, please visit www.frontiermeds.com. Follow Frontier on LinkedIn.

Media Contact
pr@frontiermeds.com


Primary Logo

Recent Quotes

View More
Symbol Price Change (%)
AMZN  245.86
+4.30 (1.78%)
AAPL  258.13
-2.20 (-0.85%)
AMD  204.16
-5.86 (-2.79%)
BAC  56.34
+0.70 (1.27%)
GOOG  325.81
+3.38 (1.05%)
META  644.93
-3.76 (-0.58%)
MSFT  477.87
-5.60 (-1.16%)
NVDA  185.00
-4.11 (-2.17%)
ORCL  189.72
-3.12 (-1.62%)
TSLA  434.86
+3.45 (0.80%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.